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Abstract
Clinical trials using monoclonal antibodies (mAb) against
cell-surface markers have yielded encouraging therapeutic
results in several cancer types. Generally, however, antican-
cer antibodies are only efficient against a subpopulation of
cancers, and there is a strong need for identification of novel
targets and human antibodies against them. We have isolated
single-chain human mAbs from a large naı¨ve antibody phage
display library by panning on a single-cell suspension of
freshly isolated live cancer cells from a human breast cancer
specimen, and these antibodies were shown to specifically
recognize cancer-associated cell-surface proteins. One of the
isolated human antibody fragments, Ab39, recognizes a cell-
surface antigen expressed on a subpopulation of cancer cell
lines of different origins. Immunohistochemical analysis of
a large panel of cancerous and normal tissues showed that
Ab39 bound strongly to several cancers, including 45% breast
carcinomas, 35% lung cancers, and 86% melanomas, but
showed no or weak binding to normal tissues. A yeast two-
hybrid screen of a large human testis cDNA library identified
the glucose-regulated protein of 78 kDa (GRP78) as the
antigen recognized by Ab39. The interaction was confirmed
by colocalization studies and antibody competition experi-
ments that also mapped the epitope recognized by Ab39 to
the COOH terminus of GRP78. The expression of GRP78 on
the surface of cancer cells, but not normal cells, makes it an
attractive target for cancer therapies including mAb-based
immunotherapy. Our results suggest that the human anti-
body Ab39 may be a useful starting point for further genetic
optimization that could render it a useful diagnostic and
therapeutic reagent for a variety of cancers. [Cancer Res
2007;67(19):9507–17]
Introduction
Breast cancer is the most frequent cancer in women and the
second leading cause of cancer deaths, exceeded only by lung
cancer (1). Clinical breast cancer management has been dramat-
ically changed with the initiation of systematic screening programs
for earlier detection and the use of adjuvant hormonal therapy,
antibody-based therapy, and chemotherapy (2, 3). These changes
are beginning to have a major impact on patient outcome, and
despite increasing incidence, breast cancer mortality is decreasing
in most of the Western world. The current goal is to expand the
repertoire of novel effective targeted therapies that will, in
combination with predictive and prognostic tests, allow individu-
alized and tailored treatment regimens that will minimize serious
side effects.
The topography of the surface of normal cells changes during
their transformation to malignant cells (4), primarily as a result of
alterations in the expression levels of lineage-specific membrane
proteins or membrane proteins involved in differentiation (5).
These changes also result from the reappearance of fetal antigens
(6) or aberrations in the tertiary structure of the exiting cell-surface
antigens, such as glycosylation (7). Several of these protein changes
have been correlated with tumor progression, metastasis, and
patient survival rates (8). Over the past three decades, substantial
efforts have focused on exploiting these cancer-associated protein
alterations to develop tumor-specific therapeutic drugs. Generation
of monoclonal antibodies (mAb) against surface receptors, where
the expression is up-regulated on cancer cells, has been the subject
of considerable scientific interest and has resulted in the
development of highly effective clinical agents for immunodiag-
nosis and immunotherapy of several cancer types (9, 10).
Glucose-regulated protein of 78 kDa (GRP78; also referred to as
BiP) is a member of the heat shock protein 70 (HSP70) family that
functions as a chaperone critical for folding, maturation, and
transport of polypeptides and proteins. GRP78 is also important in
the unfolded protein response that ameliorates stress conditions,
such as glucose starvation and hypoxia, as well as in maintaining
estrogen receptor (ER) function and protecting cells against death
(11, 12). Whereas GRP78 is constitutively expressed at low levels,
stress induces its synthesis (11). A small pool of such synthesized
GRP78 translocates to the cell surface in association with MTJ-1
(13), where it functions as a receptor for activated forms of the
plasma proteinase inhibitor a2-macroglobulin (a2M*). Further,
cell-surface GRP78 may act as a coreceptor for viruses and MHC
class I antigen presentation (14). The expression of GRP78 is highly
elevated in many cancers, correlating with malignancy, metastasis,
and drug resistance (15–18). Signaling initiated by the binding of
a2M* to GRP78 on the cell surface of human prostate cancer cells
has been shown to lead to pro-proliferative and antiapoptotic
behaviors, and it has been proposed that increased amounts of
a2M* present in some cancer patients may play a role in the
aggressive behavior of some cancers. Interestingly, autoantibodies
against GRP78 have been observed in sera of prostate cancer
patients with aggressive disease (19), and an affinity-purified anti-
GRP78 antibody preparation generated from such patients
protected cancer cells from apoptosis and induced tumor cell
proliferation similar to that observed following binding of a2M*
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(20). The identification of GRP78 on the cell surface has made it an
attractive target for cancer therapy (reviewed in ref. 21). Recently,
synthetic peptides capable of specifically binding GRP78 have been
identified and shown to target tumor cells, e.g., suppressing tumor
cell growth in vitro when coupled to Taxol or suppressing tumor
cell growth in xenograft and isogenic mouse models of prostate
and breast cancer when fused to a programmed cell death–
inducing sequence (22, 23).
To date, most clinically used mAbs against cancer-associated
antigens have been generated by conventional mouse hybridoma
technology. However, to prevent human anti-murine antibody
responses, which enhances clearance of the murine antibodies
from the circulation and precludes repeated administration, these
murine antibodies had to be ‘‘chimerized’’ or ‘‘humanized.’’
Methods wherein the entire variable region or the complementar-
ity-determining regions (CDR) of the murine mAb are grafted onto
the constant regions of human immunoglobulin Gs (IgG) are
laborious and expensive and may result in antibodies that still
retain some degree of immunogenicity (24, 25). Thus, although
recent chimeric and humanized mAbs have provided clinical
improvements, alternative methods for generating clinically
applicable human mAbs should also be pursued (26).
Phage display technology is an attractive method by which
completely human mAbs can be generated from both immune and
nonimmune sources (27, 28). Such antibodies are generally
retrieved from antibody libraries by selection against a purified
relevant subcellular component. We and others have previously
used this strategy to select antibodies against HIV-1 gp120,
nicotinic acetylcholine receptors, and thrombospondin-1 (29, 30).
However, this approach only enables isolation of antibodies against
known targets. To identify mAbs against novel antigens, we
previously selected antibody libraries against immobilized fixed cell
lines or tissue sections (31, 32). These strategies led to successful
identification of novel antibody targets, although most of these
were cytoplasmic antigens. Other groups have developed selection
strategies for isolation of cell-surface antigens primarily using cell
lines (33, 34).
In the current study, we describe an efficient procedure for
selecting human scFv antibodies to cancer-associated cell-surface
antigens by carrying out selections on viable cancer cells isolated
from freshly excised breast tumor tissue. To identify the antigen
recognized by one of the isolated human antibodies, we screened a
human testis cDNA library using the yeast two-hybrid system and
identified GRP78 as the target antigen. This scFv human antibody
recognized a large percentage of cancers of different origins, but did
not, or only weakly, recognize normal tissues, strongly suggesting its
potential clinical utility in targeted immunotherapy.
Materials and Methods
Bacterial strains and cloning. Electrocompetent amber codon
suppressing E. coli strain TG1 (Stratagene; supE thi-1 D(lac-proAB)
D(mcrB-hsdSM)5 (rK mK) [F¶ traD36 proAB lacIqZDM15]) containing
the F¶ episome for single-strand rescue was used for transformations and
preparation of phagemids and phage display libraries. The transformations
of phagemid DNA were done as described (35).
ScFv phage library. The Griffin.1 library is a large naı¨ve human scFv
phagemid library (total diversity of 1.2  109) constructed from synthetic
V-gene segments4 and was made by recloning the heavy-chain and light-
chain variable regions from the lox library vectors (36) into the phagemid
vector pHEN2.5 The Griffin.1 phagemid library resembles the Nissim library
(37) but contains diversity in the light as well as heavy chains. The helper
phage KM13 was prepared as described (38).
Isolation of living single cancer cells from a breast cancer patient
specimen. Tumor tissue from an invasive ductal carcinoma was obtained
from an 80-year-old woman immediately following therapeutic surgical
resection. The characteristics of the tumor were 100% ER positive, 80%
progesterone receptor positive, human epidermal growth factor receptor-2
negative, tumor size of 36 mm, and malignancy grade 1. After removal of fat
and necrotic parts, the tumor tissue was kept in a Petri dish containing
basal medium (DMEM, 2 mmol/L glutamine, 1 mmol/L sodium pyruvate,
1% penicillin/streptomycin, 5 mg/mL gentamicin, and 2.5 Ag/mL fungizone;
Invitrogen) on ice while being minced into 1- to 2-mm3 pieces using a razor
blade and small scissors. The minced tissue was rinsed with basal medium
followed by disaggregation by shaking at 37jC for 16 h in basal medium
containing 320 Ag/mL collagenase (Sigma-Aldrich) and 500 Ag/mL
hyaluronidase (Sigma-Aldrich). Disaggregated cells were subsequently
washed thrice in basal medium followed by centrifugation at 350  g for
10 min. After the last centrifugation, the cells were used directly for
selection or resuspended in Mammary Epithelial Cell Medium (MEGM;
Cambrex Bio Science) for further growth until the next panning.
Selection of phage libraries. Tumor cells were blocked with basal
medium/6% bovine serum albumin (BSA) in PBS mixed 1:1 for 2 h at room
temperature, after which Griffin.1 scFv phage library (1011–1012 phages)
blocked with basal medium/6% BSA in PBS mixed 1:1 for 2 h at room
temperature was added and incubated with slow tilt rotation for 2 h at
room temperature. Cells were washed 10 times with PBS by centrifuging for
5 min at 350  g between each wash. Phages were eluted by resuspending
the cells in 500 AL of a 1 mg/mL trypsin solution in PBS followed by
incubation for 10 min at room temperature with rotation. The eluted
phages were added to 1 mL of TG1 (A600 = 0.5) and incubated for 30 min at
37jC without shaking followed by plating on 1 tryptone-yeast extract agar
plates supplemented with 50 Ag/mL carbenicillin and 1% glucose. A second
round of selection on the primary tumor cells in MEGM medium was done
by rescue with the helper phage KM13, as described above. The input,
output, and output/input ratios were 1012, 8  103, and 8  109,
respectively, for the first round of panning, and 1.25  1011, 8.7  105, and
6.96  106, respectively, for the second round of panning. In other
experiments, Griffin.1 scFv phage library blocked with basal medium/6%
BSA in PBS was panned two rounds against recombinant hamster GRP78
(97% identity to human GRP78) produced in bacteria (Assay Designs, Inc.).
The recombinant GRP78 was coated on ELISA plates overnight at a
concentration of 5 Ag/mL. Phages were eluted and processed as described
above. The input, output, and output/input ratios were 4 109, 6.8  105,
and 1.7  104, respectively, for the first round of panning, and 3  1010,
4  107, and 1.33  103, respectively, for the second round of panning.
Yeast two-hybrid screening. The DNA fragment encoding Ab39 was
excised from the pHEN2 vector using NcoI and NotI restriction enzymes
and cloned into the NcoI/NotI cloning site of the pSos vector (Stratagene) to
generate bait plasmid pSL39. A human testis cDNA library, generated from a
pool of 25 normal human whole testis tissue specimens, cloned
unidirectionally into the CytoTrap pMyr XR vector, was obtained from
Stratagene. Library plasmid DNA was cotransformed into temperature-
sensitive cdc25h yeast (Mata, ura3-52, his3-200, ade2-101, lys2-801, trp1-901,
leu2-3, 112, cdc25-2, Gal+) with pSos bait plasmids and plated on synthetic
defined agar (Clontech) supplied with 20 g/L glucose or galactose. In
general, the recommendations of the manufacturer’s protocols were
followed unless otherwise stated. To select for the plasmids, both uracil
and leucine were omitted from the media. Yeast grown for 24 to 48 h at
25jC were replica plated on galactose plates and incubated at the
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that grew at 37jC were picked and expanded in liquid medium at 25jC.
Plasmid DNA was isolated according to the manufacturer’s protocol and
used to transform electrocompetent XL1-blue. The transformation was
plated on Luria broth-chloramphenicol (130 mg/L) agar plates; the resulting
colonies were expanded in 2 tryptone-yeast extract + chloramphenicol
(130 mg/L); and plasmid DNA was isolated using the miniprep kit
(Promega). The purified plasmid was used to cotransform with pSos bait
plasmids pSL39 into cdc25h yeast and reexamined for growth on galactose
or glucose solid media plates at 25jC and 37jC. The DNA insert of the
three positive library clones was amplified using the primers Myr 5¶ (5¶-
ACTACTAGCAGCTGTAATAATAC-3¶) and Myr 3¶ (5¶-CGTGAATGTAAGCGT-
GACAT-3¶; Stratagene) and fingerprinted using BstN1 and gel separation.
Antibody competition experiments. Tissue sections were processed
and stained with Ab39, as described in the immunohistochemistry
section above, except that before incubation with Ab39, sections were
preincubated with affinity-purified goat anti-GRP78 antibody (C-20, Santa
Cruz Biotechnology), affinity-purified rabbit anti-GRP78 antibody (H-129,
Santa Cruz Biotechnology), isotype-matched controls, or diluent only. The
goat anti-GRP78 antibody (C-20) recognizes the COOH terminus (amino
acids 614–654) of GRP78, produces a single band in Western blotting, and
also recognizes GRP78 in its native conformation. The rabbit anti-GRP78
antibody (H-129) is generated by immunization with a protein fragment
(amino acids 525–655) of GRP78, but the major reactivity is thought to be
directed against a region more NH2-terminal than C20 (manufacturer’s
information). This antibody also produces a single band in Western blotting
and recognizes the native conformation of GRP78. Bound Ab39 was
detected with mouse anti-M13 antibody (GE Healthcare) and horseradish
peroxidase–conjugated ‘‘Ready-to-use’’ EnVision+ polymer K4001 (Dako),
and visualized with 3,3¶-diaminobenzidine. Inhibition of Ab39 staining by
the polyclonal antibody preparations was evaluated by microscopy.
Detailed Information on ‘‘Cell lines and culture conditions,’’ ‘‘Production
of phage libraries,’’ ‘‘Production of monoclonal scFv phages,’’ ‘‘Cell ELISA and
recombinant GRP78 ELISA,’’ ‘‘Sequence analysis,’’ ‘‘Immunohistochemistry,’’
‘‘Flow cytometry,’’ and ‘‘Cell growth inhibition assay’’ are provided in
Supplementary data.
Results
Selection of cancer cell–binding phage-displayed scFv anti-
bodies. To identify and clone human antibodies against breast
cancer cell-surface molecules, single live breast cancer cells were
obtained from a freshly excised breast tumor of a patient with
ductal carcinoma and used for selection of a large naı¨ve human
scFv phage display library. Following two rounds of biopanning, a
100-fold amplification of the amount of eluted phage was observed,
indicating enrichment for cell-binding clones. Single clones from
the two rounds of panning were selected and screened for binding
to a panel of breast cancer cell lines by direct phage ELISA,
revealing a set of clones that bound at least to one of the cell lines
and not with control wells containing only media. Following
further analysis, antibody Ab39, obtained from the first round of
panning, and antibody Ab83, obtained from the second panning
round, were selected for further characterization. As shown in
Table 1, analysis of the binding of phage antibodies Ab39 and Ab83
to five breast cancer cell lines of different origins and a T-cell
leukemia line showed that both Ab39 and Ab83 bound to all the
cancer cell lines, albeit at varying intensities. Whereas Ab39
showed efficient binding (+++/++) only to BrCa-MZ-01, MDA-MB-
231, and Hs578T, Ab83 efficiently bound (+++/++) to all cell lines
except MDA-MB-231. A control, AbK2, a scFv-expressing phage
chosen randomly from the original library, showed no binding to
the cell lines.
The DNA encoding the variable heavy-chain and light-chain
genes of the two selected antibody fragments was sequenced and
the amino acid sequences were deduced (Table 2). The two scFv
antibodies, Ab39 and Ab83, have heavy chains from two different
VH families. In contrast, both had E light chains from the same
family, although the CDR3 regions differed.
Immunohistochemical analysis of normal and cancerous
tissues. The tissue distribution of the antigens recognized by
Ab39 and Ab83 was examined using a panel of formalin-fixed,
paraffin-embedded cancer and normal tissues. As shown in Fig. 1
and Table 3A , Ab39 bound to cancers of different origins,
including breast carcinoma, malignant melanoma, ovarian carci-
noma, lung adenocarcinoma, lung sqamous cell carcinoma, and
seminoma. Generally, however, not all cancers within a certain
cancer subtype were stained with Ab39 [i.e., 45% (22 of 49) of
breast carcinomas, 35% (7 of 20) of lung cancers, and 86% (6 of 7)
of melanomas]. The staining intensity varied within tumors and
between tumors from different patients. Ab83 also bound to
cancers of different origins but recognized a higher frequency of
cancers within a certain subtype compared with Ab39 [i.e. 65%
(32 of 49) of breast carcinomas, 50% (10 of 20) of lung cancers, and
all (7 of 7) melanomas]. Similar to Ab39, the staining intensity of
Ab83 varied within tumors and between different patients. In the
Table 1. Cell ELISA showing Ab39 and Ab83 binding to different cancer cell lines






Tumorigenicity Invasiveness Ab39 Ab83 AbK2
BrCa-MZ-01 * MBC P + + Y n.d. +++ +++ 
Hs578T HTB-126 CS P   N Highly invasive +++ +++ 
MCF-7 HTB-22 IDC M (Pl) + + Y Weakly invasive + +++ 
MDA-MB-157 HTB-24 MBC M (Pl)   Y n.d. + ++ 
MDA-MB-231 HTB-26 IDC M (Pl)   Y Highly invasive ++ + 
Jurkat TIB-152 Leukemia T-cell nd nd + +++ 
RPMI medium   
NOTE: Characteristics of the cell lines analyzed are included. +++, strong binding; ++, intermediate binding; +, weak binding; , no binding.
Abbreviations: PgR, progesterone receptor; MBC, medullary breast cancer; CS, breast carcinoma stellate cell type; IDC, infiltrating ductal carcinoma
(breast); P, primary breast tumor; M, metastasis; Pl, pleura fluid.
*A kind gift from Prof. Mo¨bus, Universita¨tklinikum, Ulm, Germany.
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cancer specimens, Ab39 and Ab83 stained only the cancer cells, not
the connective tissue, blood vessels, or muscles. The control AbK2
did not stain the cancer cells or adjacent normal tissue.
Further tissue sections of formalin-fixed, paraffin-embedded cell
pellets of different cancer cell lines were examined for staining
by Ab39 and Ab83. As shown in Fig. 2A , Ab39 and Ab83 bound
intensely to the cell surface of Hs578T, MCF-7, and MDA-MB-157
cells and also stained the cytoplasm. Interestingly, not all Hs578T
and MDA-MB-157 cells were stained with the same intensity, and a
subpopulation of cells was not stained at all. No significant binding
to Hs578T, MCF-7, and MDA-MB-157 was observed with the
control AbK2.
Figure 1. Staining pattern of human mAbs Ab39 and Ab83 in human cancer biopsies and its comparison with anti-GRP78 staining as determined by
immunohistochemical analysis. Ab39 (A), Ab83 (B ), AbK2 (negative control; C ), and rabbit anti-GRP78 antibody (H-129; D ) were used to stain human cancer tissues,
including lobular breast carcinoma (a), malignant melanoma (b), lung adenocarcinoma (c ), and lung squamous cell carcinoma (d). Ab39, Ab83, and rabbit anti-GRP78
antibody stained cancer cells in all four specimens, whereas no staining was observed in adjacent normal tissue. No staining of cancer cells or adjacent normal
tissue using control AbK2 was observed (C ).
Table 2. Deduced amino acid sequences of the heavy-chain and light-chain CDR3 regions of Ab39, Ab83, and Ab99
Clone Variable heavy segment Variable heavy CDR3 Variable light segment Variable light CDR3
Ab39 VH1-24 FELPMGCT VL3-31 NSRDSSDHGYV
Ab83 VH2-70 MCKNYPGRFY VL3-31 NSRDSSGDHLV
Ab99 VH3-72 RRRFKNR VK1-O12 QQSYSSPYLT
NOTE: The closest germ-line genes and VH and VL families for each clone are also shown.
Cancer Research
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A large panel of different normal tissues was also examined for
Ab39 and Ab83 staining (Fig. 2B ; Table 3B). Immunohistochemical
analysis showed that Ab39 did not react with any of the normal
tissues except a subpopulation of cells in the seminiferous tubule of
testis. These cells were determined to be predominantly sperma-
tocytes with some spermatids, and no staining was observed in
spermatogonia, spermatozoa, or Sertoli cells. In contrast, Ab83
stained cell populations in a broad variety of normal tissues,
including a cell population present in the submucosa of the small
instestine, the distal convoluted tubule of the kidney, and, to a
lesser extent, the proximal convoluted tubule of the kidney, normal
abortion tissue, placenta, spermatocytes and spermatids in normal
testis, and a cell population in the lymphoid follicles of tonsil
(Fig. 2B). No binding to these normal tissues was observed with the
control AbK2.
Binding of scFv antibodies to the surface of breast cancer
cell lines. Ab39 and Ab83 were tested for binding to a panel of
unfixed breast cancer cell lines (Hs578T, MDA-MB-157, MCF-7,
and MDA-MB-231) by flow cytometry. Ab39 bound to the cell
surface of all four cell lines, whereas Ab83 bound to the Hs578T and
Table 3. Immunohistochemical analysis of the reactivity of Ab39, Ab83, and anti-GRP78 antibody (H-129) with cancerous (A)
and normal (B) tissues (npositive/n total)
(A)
Tumor type Ab39 Ab83 AbK2 (control) Anti-GRP78 antibody
Breast carcinoma 22/49 32/49 0/49 28/49
Lymphoma 1/2 1/2 0/2 1/2
Lung carcinomas total 7/20 10/20 0/20 8/20
Adenocarcinoma 2/4 2/4 0/4 2/4
Large-cell carcinoma 1/2 2/2 0/2 1/2
Small-cell carcinoma 1/2 1/2 0/2 1/2
Planocellular Carcinoma 3/12 5/12 0/12 5/12
Malignant fibrous Histocytoma 0/1 0/1 0/1 0/1
Malignant melanoma 6/7 7/7 0/7 6/7
Mesothelioma 0/1 0/1 0/1 0/1
Ovary carcinoma 1/1 1/1 0/1 1/1
Pheochromocytoma 0/1 0/1 0/1 0/1
Renal cell carcinoma 0/1 0/1 0/1 0/1
Seminoma 1/1 1/1 0/1 1/1
Medullary thyroid carcinoma 1/1 1/1 0/1 1/1
(B)
Tissue Ab39 Ab83 AbK2 (control) Anti-GRP78 antibody
Bladder  +  +
Bowel    
Cerebellum    
Cerebrum    
Gallbladder    
Kidney  +  +
Liver    
Lung    
Muscle    
Esophagus    
Ovary    
Parathyroid gland    
Placenta  +  +
Prostate    
Rectum    
Skin    
Small intestine  +  +
Testis + +  +
Thymus    
Thyroid gland  +  +
Tonsil  +  +
Ventricle    
NOTE: AbK2 was used as negative control.
Human mAb Recognizing GRP78 on Cancer Cell Surface
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MDA-MB-157 cell lines, but only weakly to MCF-7 or MDA-MB-231
(Fig. 3A). The control antibody, AbK2, showed no significant
binding to any of the cell lines.
A second set of experiments focusing on the most promising
clone, Ab39, examined cell-surface binding to three other beast
cancer cell lines, BrCa-Mz-01, 2C5, and 4A4, as well as to Jurkat
T cells (Fig. 3B). Ab39 bound to all three breast cancer cell lines but
showed no surface staining of Jurkat T cells. As shown in Fig. 2A
and B , a complete shift in intensity of all the Ab39 or Ab83 stained
cells was not always observed, suggesting that not all cells were
equally stained, and some remained unstained, in agreement with
our cytochemistry results.
Western blotting. To determine the approximate mass of
antigens recognized by Ab39 and Ab83, lysates of the MCF-7,
Hs578T, and MDA-MB-231 cell lines were separated by Western
blotting and stained by the two antibodies. No specific bands were
recognized by the two antibodies, suggesting that they recognized
conformationally dependent epitopes.
Identification of the target antigen for Ab39 using yeast two-
hybrid screening. To identify the antigen recognized by Ab39, a
yeast two-hybrid screen of a large human testis cDNA library was
done using the CytoTrap two-hybrid system, which allows
identification of glycosylated antigens, an important aspect
because the target antigen of Ab39 is expressed on the cell surface.
The cDNA encoding Ab39 cloned into the pSOS to be used as bait
was cotransformed with the testis library in the pMyr XR vector.
The screen identified three clones that permitted growth at 37jC of
yeast harboring plasmids expressing Ab39 (pSL39). Fingerprinting
indicated that the cDNA inserts of these three clones were
identical. Sequencing of the insert of one of the clones revealed a
cDNA that encodes the 166-amino-acid COOH-terminal region of
human GRP78 (amino acids 489–654; 99% identity) as the Ab39
interacting protein.
Verification of GRP78 as the target antigen and epitope
mapping. To verify that GRP78 was the target antigen for Ab39,
serial sections of the same tissue specimens and cell lines initially
analyzed with Ab39 and Ab83 were examined using two polyclonal
antibodies directed against the COOH-terminal part of GRP78. As
shown in Figs. 1 and 2 and Table 3, the staining pattern of rabbit
anti-GRP78 antibody (H-129) was very similar to that observed
with Ab39 and Ab83. A similar staining pattern was also observed
with the goat anti-GRP78 antibody (C20; data not shown).
Importantly, Ab39 seemed to be better at discriminating cancer
from normal tissue, perhaps due modification of the target epitope
on GRP78.
To more precisely determine the epitope of Ab39 within the
COOH-terminal domain of GRP78, competition experiments
between Ab39 and the two polyclonal ant-GRP78 antibodies were
done using serial tissue sections of tumors with high GRP78
expression. As shown in Fig. 3C , C20 goat anti-GRP78 antibody
directed against the COOH terminus of GRP78 (amino acids 614–
654) significantly inhibited Ab39 staining, whereas the H-129 rabbit
anti-GRP78 antibody and isotype-matched control antibody did
not, showing the epitope of Ab39 to be within the amino acid
region 614–654 of GRP78.
To expand our panel of human monoclonal anti-GRP78
antibodies, we selected the large naı¨ve human scFv phage display
library against recombinant GRP78 coated on ELISA plates. One
additional human anti-GRP78 scFv, Ab99, was identified from the
second round of panning (Table 2). Whereas this scFv bound
efficiently to recombinant GRP78, it did not bind to the control
antigen, as shown by ELISA (Fig. 3D). Interestingly, Ab39 and Ab83
did not react significantly with the recombinant GRP78 (hamster
GRP78; 99% identity to human GRP78). Comparing the sequences
of human and hamster identified one amino acid change (amino
acid 649, Hu:A-Ham:S) in the region where Ab39 was mapped.
Further analysis of potential glycosylation sites on GRP78 identified
one O-glycosylation site (amino acid T643) in the COOH terminus
of GRP78 to which Ab39 was mapped. Because the recombinant
hamster was produced in bacteria and thus lacks glycosylation, the
ELISA results suggest that the binding of Ab39 may be influenced
by glycosylation or may involve amino acid 638.
Cell growth inhibition assay. Because a human polyclonal anti-
GRP78 antibody preparation purified from serum of prostate
cancer patients with autoantibodies against GRP78 has been
shown to increase tumor cell proliferation in vitro (R), we examined
the effect of Ab39 and Ab83 on the growth of different breast
cancer cell lines in culture with a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay. High concentrations of puri-
fied Ab39, Ab83, and control AbK2 scFv failed to alter the growth of
MDA-MB-231, BrCa-MZ-01, or MDA-MB-157 cells (data not
shown).
Discussion
The search for human mAbs against novel cell-surface molecules
that may be used as targets for cancer therapies has recently led to
the development of several novel technologies that efficiently
generate such antibodies. Phage display is one such technology
that, with the development of improved selection and screening
methods, has proved very useful in isolating antibodies with
specificities against undefined cellular disease markers. Antibodies
against novel cell specificities have been retrieved from immune
libraries developed using materials from patients with malignan-
cies or autoimmune conditions, thus reflecting the immune
repertoire in these individuals (31, 32, 39). In nonimmune libraries,
the most promising application is the ability to generate human
antibodies with specificities that are not normally, or only rarely,
generated by the natural human antibody response or by the
immune response of immunized normal or human IgG transgenic
mice.
Our selection strategy uses freshly isolated live cancer cells from
a clinically excised breast cancer specimen to isolate a panel of
breast cancer cell-surface–reactive antibodies from a large
Figure 2. Staining pattern of human mAbs Ab39 and Ab83 in breast cancer cell lines and normal human tissues and its comparison with anti-GRP78 staining
determined by immunohistochemical analysis. Ab39 (A ), Ab83 (B), AbK2 (negative control, C ), and rabbit anti-GRP78 antibody (H-129, D ) were used to stain breast
cancer cell lines Hs578T (a), MCF-7 (b), and MDA-MB-157 (c ) and normal tissues including testis (d), kidney (e), intestine (f ), tonsil (g), and lung (h). Ab39 and
Ab83 showed cell-surface staining of the three breast cancer cell lines. In normal tissues, Ab39 did not stain a large panel of normal tissues but showed staining in
testis restricted to spermatocytes and spermatids of the seminiferous tubule, and no staining in spermatogonia, spermatozoa, or Sertoli cells. Ab83 also stained
spermatocytes and spermatids in normal testis (Bd), the distal convoluted tubule, and, to a lesser extent, the proximal convoluted tubule of the kidney (Be ), as well as
cells in the submucosa of the small instestine (Bf ) and the lymphoid follicles of tonsil (Bg ), but not in lung (Bh) or several other normal tissues. AbK2 did not stain
the breast cancer cell lines or the normal tissues (C ), whereas rabbit anti-GRP78 antibody (H-129) showed a staining pattern similar to Ab83 (D ).
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nonimmune human scFv library. Two human scFv antibodies, Ab39
and Ab83, which are reactive with many tumors of different
histologic origins but show no or weak binding to normal tissues,
were isolated. Identification of the antigen recognized by Ab39 was
less straightforward because the epitope recognized by the
antibody is probably conformational dependent, and the antigen
is therefore not detected in Western blots. Standard immunopre-
cipitation experiments often lead to insufficient material for mass
Figure 3. Biochemical characterization of human scFvs Ab39, Ab83, and Ab99. A, flow cytometry analysis of scFv phage antibodies Ab39 and Ab83 binding to different
cancer cell lines. In one set of experiments, Ab39 and Ab83 were tested for binding to the four breast cancer cell lines MDA-MB-231, Hs578T, MDA-MB-157, and
MCF-7. AbK2 was included as negative control. B, a second set of experiments assessed Ab39 binding to three other breast cancer cell lines, NM-2C5, M-4A4, and
MDA-MB-157, and the Jurkat T-cell line. M13 phage was used as negative control. In both experiments, bound scFv phages were detected using a phycoerythrin-
labeled anti-M13 antibody. C, inhibition of human monoclonal Ab39 staining by polyclonal anti-GRP78 antibody: Serial tissue sections of human melanoma
(first column ) and a ductal breast cancer (second column ) were incubated with an anti-GRP78 antibody before adding Ab39. A marked reduction in Ab39 staining was
observed with the C20 goat antibody directed against the COOH terminus of GRP78 (second row ), whereas strong staining was observed when Ab39 was
applied alone (first row), with a rabbit anti-GRP78 antibody, H-129 (third row ), or with isotype-matched control antibody (fourth row ). D, binding of scFv phage
antibodies Ab39, Ab83, and Ab99 to bacterial expressed recombinant hamster GRP78 and bovine serum albumin (control) by ELISA.
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spectrometry analysis, and therefore a yeast-two hybrid system
screen was done using Ab39 as bait. The CytoTrap yeast two-hybrid
system was used, which monitors protein interactions at the
plasma membrane through activation of a Ras-dependent signal
pathway by hSos protein (40), and thus enables identification of
interaction partners not identifiable by conventional yeast two-
hybrid systems, including proteins that require posttranslational
modification in the cytoplasm, are transcriptional activators or
repressors, and are toxic to yeast in conventional two-hybrid
systems. Because our immunohistochemical analysis had shown
that the target antigen was expressed in normal testis, a large testis
cDNA library was screened with the yeast-two hybrid system.
Because GRP78 has been reported to be constitutively expressed in
several normal tissues, its identification as the target antigen came
as a bit of a surprise as we would have expected to see staining
with Ab39 in many normal tissues. On the other hand, the result
correlated well with the previous observation that increased levels
of GRP78 are found on the surface of spermatocytes and some
spermatids in normal testis (41) compared with other normal
tissues, and that increased GRP78 levels are present in a substantial
number of cancers. Comparison of the staining patterns of the two
human scFv antibodies and two polyclonal anti-GRP78 antibodies
also showed colocalization, with Ab83 showing identical staining
with the two polyclonal anti-GRP78 antibodies in normal tissues.
Although Ab39 exhibited slightly less intense staining of the
cancers compared with Ab83 and the polyclonal anti-GRP78
preparations, Ab39 seemed to be better at discriminating cancer
from normal tissue. This could relate to the particular epitope on
GRP78 recognized by Ab39 that may be modified in cancer cells
(e.g., posttranslational modification). The influence of fixation on
the epitopes recognized by the two scFv should also be considered.
Flow cytometric and immunocytochemical analyses of Ab39
staining in different breast cancer cell lines revealed significant
variability from cell to cell within a given cell line. Whereas
some cells stained intensely, others exhibited weak or no
staining, and these subpopulations could not be distinguished
by size or granularity. We previously observed similar staining
intensity variability in breast cancer cell lines using an antibody
reactive with another antigen (cancer/testis antigen GAGE; ref.
42). In those studies, only 5% to 30% of the experimental cancer
cell line stained for GAGE, showing that expression of this
antigen was not associated with a specific genotype but was
linked to a specific phenotype (e.g., a specific stage in the cell
cycle). Because the effectiveness of new therapeutics requires
that they also target the cancer stem cells, it would be important
to evaluate whether our human mAbs also recognized these
cells. The phenotype of breast cancer stem cells is still not fully
defined, but they are generally characterized by being CD44+ and
CD24 (43). Two of the breast cancer cell lines, NM-2C5 and
M-A4A, which were shown to be targeted by our human scFvs,
indeed exhibited the CD44+/CD24 phenotype on all cells.6
Interestingly, this cell line also exhibited features generally
observed in breast cancers of the basal-like subtype, which has
been suggested to be of stem cell origin (44). These preliminary
results suggest that our human anti-GRP78 mAbs will recognize
cancer stem cells.
Our immunohistochemical studies were done using scFv
expressed on phage, a method that has been considered
problematic because the phage particles have a tendency to bind
unspecifically. However, we optimized a protocol that largely
overcomes this. No or very limited unspecific binding was observed
using a panel of control phages that express irrelevant scFv
antibodies, including AbK2, selected from the starting library and
verified to express scFv antibody. The use of scFv expressed on
phage instead of soluble scFv in the initial screening provides
significant amplification of the immunohistochemical detection
signal. A phage particle may express more than one scFv, resulting
in increased avidity, which may be significant because some
antibodies retrieved from naı¨ve libraries may be of modest affinity
compared with those isolated from immune libraries. Moreover,
the use of an anti-M13 antibody as secondary antibody may
significantly amplify the signal because the target of this antibody,
protein VIII, is expressed in 2,500 to 3,000 copies on the phage
surface.
Competition experiment revealed that Ab39 is directed against
the COOH terminus of GRP78. The conformation and orientation
of GRP78 in the cell membrane is not well characterized. GRP78,
like other HSP proteins, consists of two domains: the 44-kDa NH2-
terminal domain, which is responsible for GRP78 ATPase activity,
and a 20-kDa COOH-terminal polypeptide binding domain. In
addition, it contains a highly helical and variable 10-kDa COOH-
terminal tail of unknown function (45). Because GRP78 does not
contain a transmembrane domain, it was uncertain how GRP78
became exposed on the cell surface. Recent results, however, have
shown that GRP78 is likely translocated and present at the cell
surface associated with the transmembrane protein MTJ-1, which
is also an accessory protein for GRP78 catalytic activity (13).
The J domain of MTJ-1 interacts with GRP78, stimulates its
ATPase activity, and functions as its cochaperone in protein
folding and translocation of newly synthesized polypeptides
across ER membranes (46). Interestingly, GRP78, like other
HSP70 proteins, self-associates into multiple oligomeric species
(47, 48). The COOH-terminal domain of GRP78 has been shown to
be responsible for the oligomeric properties of the protein (48).
Binding of unfolded peptidic substrate onto the COOH-terminal
domain, or binding of ATP onto the NH2-terminal domain,
promotes depolymerization and stabilization of BiP monomers
(48). A recent study examining the interaction of dengue virus
serotype 2 with the cell surface identified GRP78 as a interaction
partner and showed that both antibodies directed against both
the NH2 and COOH termini of GRP78 altered the binding of the
virus to the cell surface (49), indicating that both the NH2 and
COOH termini of GRP78 are accessible at the cell surface.
A human polyclonal antibody preparation of affinity-purified
GRP78 from serum of prostate cancer patients with autoantibodies
against GRP78 has been shown to increase tumor cell proliferation
and inhibit apoptosis in vitro (20). This human polyclonal anti-
GRP78 antibody was directed against the same region as that
recognized by GRP78 physiologic agonist, a2M*, and mapped to
amino acids 98 to 115 present in the more NH2-terminal region of
GRP78. Another study examining Kringle 5 of human plasminogen,
which inhibits angiogenesis by inducing apoptosis of proliferating
endothelial cells, showed that Kringle 5 also induces apoptosis
of stressed HT1080 fibrosarcoma cells by binding to the NH2
terminus of GRP78 (50). Due to these opposing observations, we
tested whether Ab39 and Ab83 expressed as soluble scFvs were
capable of influencing the cell growth of a panel of breast cancer
cell lines, but no change in growth rate was observed. This may not
come as a surprise because the scFvs bind to a different region of6 R. Leth-Larsen, R. Lund, and H.J. Ditzel, unpublished data.
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GRP78 than the anti-GRP78 autoantibody preparation and Kringle
5 and do not diminish the potential of the human anti-GRP78
mAbs in clinical therapeutics. Recently, a study using a cyclic
GRP78 binding peptide showed that its linkage to Taxol resulted in
specific and efficient tumor growth suppression in vitro (23). In
another study, using a different GRP78 binding peptide fused to a
programmed cell death–inducing sequence resulted in efficient
tumor growth suppression in xenograft and isogenic mouse
models of prostate and breast cancer (22). Similarly, the human
anti-GRP78 mAbs may be used for cancer-specific delivery of
cytotoxic agents and radioisotopes. In addition, whole anti-GRP78
mAbs may potentially mediate antibody-dependent cellular
cytotoxicity dependent on the surface expression levels of GRP78
and the affinity of mAb.
In conclusion, our efficient selection strategy led to the isolation
of the human scFv mAb Ab39 that may have clinical applications as
both a therapeutic drug and an imaging agent. Because the
antibodies are isolated from human antibody repertoires, they
should not be immunogenic when given to patients. Following
affinity maturation by genetic engineering, it may be beneficial to
transform Ab39 into a whole human IgG antibody to increase the
recruitment of effector cells to the targeted cancer cells, whereas
the use of single-chain molecules may have advantage as an
imaging agent.
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